28th August 2026
Read More
Welcome
This is MU-JHU!
We are an indigenous medical research and care organization in existence since 1988, located on Upper Mulago Hill in Kampala. MU-JHU is a key player in contributor to new knowledge in HIV prevention, care, and treatment, community HIV programs as well as non-HIV research, and training. We envision a Uganda where all women, children, adolescents, and their families enjoy full health and wellbeing. Our mission is to be a Centre of excellence in health research, and care for women, adolescents, children, and their families.
Our Mission
To undertake health research, provide health-services and conduct training; focusing on HIV, prevalent and emerging conditions affecting the well-being of women, children, youth and families.
Our Research Domains
- Perinatal HIV/TB Prevention and Care
- Pediatric and Infant Health
- Growth, Neurodevelopment and Bone Health
- Bacterial Infections and Vaccine Development
- Blood Safety and Infection Prevention
Clinical Trial Phases
- Phase I (Safety & Dosage)
- Phase II (Effectiveness & Side Effects)
- Phase III (Efficacy & Comparison)
- Phase IV (Long-term/Post-marketing)
- Adaptive Trials
See Clinical Research Regulations in Uganda
Announcements
Scholarships
Procurement
Call For Applications
Disposal of Used Vehicles
New Studies
Our latest protocols and clinical trials
- Gut Microbiome and Depression among People Living with HIV in Uganda. Principal Investigator – Betty Nyangoma
- An open-label randomised controlled trial comparing novel combination and currently used antibiotic regimens for the empiric treatment of neonatal sepsis with a run-in confirmatory pharmacokinetic phase: NeoSep1. Principal Investigator – Dr. Maxensia Owor
- IMPAACT 2024: Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV. Principal Investigator – Dr. Eric Wobudeya
- A phase 2, Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (RAD-TB). Principal Investigator – Dr. Deo Wabwire
- A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women. Principal Investigator – Dr. Flavia Matovu Kiweewa
New Articles
Our Work
Our Partners
© 2022 MU-JHU Research Collaboration. All rights reserved